CMAB Biopharma (Suzhou) Inc., a biologics contract manufacturing and development organization (CDMO), has appointed Ye Shi as the head of quality. He will be responsible for the overall management of the quality system within CMAB.
 
Yongzhong Wang, chief executive officer, CMAB, said, “We are very pleased to welcome Mr. Ye Shi to CMAB. In the Chinese biopharmaceutical and CDMO industries, quality experts like Mr. Ye Shi are very rare. He has both front-line practical experience as well as success in managing an entire company quality system both at home and abroad. We believe that his leadership will greatly strengthen CMAB's world-class CDMO quality system and provide our customers with more outstanding services.
 
Over the last 30 years, Mr. Ye Shi has worked in biopharmaceutical companies in both China and the U.S. and promoted their quality management towards a world-class level. Before joining CMAB, he served as the deputy general manager and quality assurance director at QILU Pharmaceutical Co., Ltd. There, he successfully led the team to pass the pre-inspection approval (PAI) of antibody drugs by the Chinese Centre for Drug Evaluation (CDE), which subsequently successfully entered commercialization.